RJ Tesi

RJ Tesi joined Ferghana Partners in 2025 to provide guidance on matters involving CNS, inflammation, immunology and longevity.

For the prior ten years he was President/CEO at INmune Bio, a public company, focusing primarily on neuro-inflammation in Alzheimer’s as well as developing CORDStrom™, a cell therapy for Recessive Dystrophic Epidermolysis Bullosa and potentially for osteoarthritis of the knee. After eight years in research, teaching and surgery roles at universities, Dr Tesi entered the corporate world at Sangstat Medical where his career embraced diverse activities ranging from Senior Vice President- Marketing to Investor Relations to Strategic Development & Medical Affairs to Clinical Development & Medical Affairs.

RJ then became EVP- Clinical Development, Medical & Regulatory Affairs at Cellerant Therapeutics to develop its cell therapy programs: a cancer support treatment and another to combat radiation bioweapons in addition to cancer stem cell/antibody program to induce apoptosis in myeloid leukemia cancer stem cells. Following that experience,, RJ founded several biotech companies and held senior development and commercial leadership roles in them.

Dr. Tesi has co-authored many peer-reviewed publications and has made presentations of medical/scientific topics at major conferences.

RJ received his medical degree from Washington University after obtaining a Bachelor of Science, cum laude from Utah State University.